Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab
BackgroundLoss of skeletal muscle mass may serve as a valuable indicator of treatment efficacy and survival in individuals with lung cancer undergoing immunotherapy. This investigation sought to pinpoint accessible markers that could reflect the presence of muscle degradation.MethodsA retrospective...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2025-08-01
|
| Edice: | Frontiers in Oncology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1635321/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
